Unpacking the Potential of HER3-Targeted Therapy in NSCLC

CCO Oncology Podcast

English - December 26, 2023 19:43 - 15 minutes - 14.2 MB
Courses Education Health & Fitness Medicine essential thrombocythemia myelofibrosis oncology cme skin cancer acute myeloid leukemia kidney cancer melanoma gastrointestinal cancer prostate can Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Recent Advances in ADCs and Rationale for HER3 as a Target in Lung Cancer

Next Episode: Current Considerations for Adverse Event Management With HER3-Directed Agents

This second episode in a 3-part series on HER3-targeted agents in NSCLC covers current clinical trials with HER3-targeted therapy, including:

Recent data on patritumab deruxtecan (HER3-DXd) in the HERTHENA-Lung01 trialThe EGFRxHER3 bispecific antibodies BL-B01D1 and izalontamabThe HER2xHER3 bispecific antibody zenocutuzumabThe HER3-targeted antibody–drug conjugate SHR-A2009

Presenters in this series include:

Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Helena Yu, MD
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Supported by an educational grant from Daiichi Sankyo, Inc.

Link to full program, including a downloadable highlights slideset:
https://bit.ly/48ecElW